GALT GALT
Company Profile ↓Company Overview
GALT (GALT) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 24.1%, reflecting efficient use of shareholder capital.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -13.93% |
| 6 Months: | -4.92% |
| 3 Months: | +38.57% |
| 1 Month: | -32.97% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.12 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 24.1%.
CONS
- Trading 52.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | -4.84M | -3.38M | -3.48M | - | -4.84M | -4.66M | -5.90M | - | -6.81M | -5.53M | -4.54M | -4.95M | -4.51M | -4.41M | -4.18M | -3.76M | -2.68M | -2.37M | -3.02M | -2.86M | -3.58M | -6.10M | -5.93M | -6.32M | -8.19M | -8.24M | -9.94M | -9.66M | -8.12M | -10.34M | -9.00M | -9.17M | -9.65M | -11.29M | -9.07M | -7.90M | -4.62M | -4.20M | -4.08M |
| Net Income | -2.80M | -5.11M | -3.43M | -3.52M | -3.73M | -4.83M | -4.64M | -5.89M | -4.67M | -6.80M | -5.52M | -4.53M | -4.94M | -4.51M | -4.41M | -4.26M | -3.84M | -2.75M | -2.38M | -3.00M | -2.78M | -3.56M | -6.11M | -5.94M | -6.34M | -8.45M | -8.52M | -9.93M | -9.61M | -8.60M | -11.53M | -9.11M | -10.43M | -11.49M | -12.37M | -11.22M | -9.63M | -7.52M | -8.18M | -5.05M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.10 | -0.11 | -0.15 | -0.14 | -0.17 | -0.16 | -0.14 | -0.19 | -0.15 | -0.24 | -0.19 | -0.20 | -0.18 | -0.15 | -0.12 | -0.13 | -0.08 |
| R&D Expense | - | 2.77M | 1.59M | 1.98M | - | 3.14M | 2.60M | 4.46M | - | 4.38M | 4.23M | 3.29M | 3.77M | 3.44M | 3.50M | 2.30M | 1.48M | 1.50M | 646.00K | 1.52M | 1.50M | 2.14M | 4.68M | 4.78M | 4.90M | 6.45M | 6.61M | 8.06M | 8.07M | 6.60M | 8.80M | 7.37M | 7.73M | 8.05M | 9.81M | 7.59M | 6.49M | 3.26M | 2.61M | 2.23M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -4.88M | -10.41M | -9.90M | -12.10M | -15.43M | -20.08M | -21.48M | -16.25M | -13.60M | -13.44M | -23.44M | -30.18M | -38.35M | -38.07M | -42.43M | -20.09M |
| Net Income | -5.63M | -10.91M | -9.68M | -12.09M | -15.79M | -20.03M | -21.44M | -16.23M | -13.90M | -13.29M | -23.46M | -30.53M | -38.78M | -41.07M | -47.05M | -30.84M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.41 | -0.52 | -0.65 | -0.74 | -0.76 | -0.48 |
| R&D Expense | 1.07M | 3.55M | 4.53M | 5.69M | 8.43M | 13.11M | 15.32M | 11.72M | 6.47M | 7.47M | 17.98M | 23.82M | 31.74M | 32.13M | 36.57M | 14.29M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 6.30M | 6.61M | 9.56M | 10.71M | 29.68M | 26.41M | 15.79M | 4.16M | 9.01M | 48.47M | 29.60M | 41.83M | 21.29M | 28.20M | 17.50M | 19.53M |
| Total Equity | -4.47M | -1.69M | -2.12M | 1.17M | 1.48M | 21.20M | 18.04M | 10.29M | -530.00K | 5.17M | 43.87M | 22.47M | 893.00K | -33.92M | -61.96M | -104.79M | -127.92M |
| Cash & Equivalents | 251.00K | 5.89M | 6.40M | 9.36M | 10.49M | 29.13M | 25.85M | 15.36M | 3.05M | 8.25M | 47.48M | 27.14M | 39.65M | 18.59M | 25.66M | 15.12M | 17.72M |
| Total Liabilities | - | 1.78M | 2.21M | 1.64M | 2.49M | 1.70M | 1.36M | 3.78M | 2.97M | 2.11M | 2.87M | 5.41M | 39.21M | 53.48M | 88.44M | 120.56M | 145.73M |
| Current Liabilities | - | 1.77M | 2.21M | 1.64M | 2.49M | 1.70M | 1.36M | 3.78M | 2.97M | 2.11M | 2.82M | 5.40M | 9.03M | 13.01M | 15.68M | 35.41M | 8.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.10M | -5.68M | -7.50M | -7.48M | - | - | -15.89M | -10.18M | -10.85M | -20.60M | -24.31M | -31.06M | -32.97M | -41.77M | -23.88M |
| Investing Cash Flow | - | -15.00K | 64.00K | - | - | - | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 8.74M | 6.20M | 10.40M | 8.61M | - | - | 3.58M | 15.38M | 50.08M | 263.00K | 36.81M | 10.00M | 40.03M | 31.23M | 26.48M |
| Capital Expenditure | - | -5.00K | -5.00K | -0 | -0 | -0 | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | -5.68M | -7.50M | -7.48M | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 332.3% | 513.6% | -830.5% | -816.2% | -74.5% | -111.0% | -208.3% | 3,063.2% | -268.6% | -30.3% | -104.4% | -3,418.5% | 114.3% | 66.3% | 44.9% | 24.1% |
| ROCE % | -107.8% | -236.7% | -124.9% | -147.1% | -55.2% | -80.2% | -178.8% | -1,361.9% | -197.2% | -29.4% | -96.9% | -92.0% | -463.6% | -304.0% | 236.9% | -174.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GALT
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Common Stock by Chairman Richard E. Uihlein - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxORF9UVUNvdVhiYXlSM0xCdGNGYTBBUDNocWxtcG5IdjBZVDJRdVc5a19GdE9tS1lBMlY3RHVMNzdIYTgxSlFpQWtVVldyTjUtZ2pZUk40N3FrSkNXZG9URUdJd0xCZHRrWnNITVRwTklNM0p0cURQYnJSSzgwRHVkQzIyeGZ3Qnkxb2lPTl…
Galectin Therapeutics (GALT) director converts credit notes into stock - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNWGdQZ013MjQxWHBzSTRFOC00VjBoQ1hxeF9DZUVycXl5MVZWUnJ2S3I2QkdyVU1HdGVTQ3V5cHNqOW4tLVRKUTl1RVI5NllpbWxENmxQSDRIdF9WVGw3RkFYN29ESDdqU0oxak5KTXJyX3QtY24yNTd5MjY1SmFvM2xWdlNzNVhaSnpQcG…
Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOMWdLQTBiYkI4N19UMldIWnZtSTBoVjJVNW44VURQNHd5YTdBVFp4Y180X1lwVVo2YlhFSHAxNlVBX3pRZlVpV3pLVTJpYkdPbEREVVEzWDh5RURWLWxYWWo0bGpkelk5TlgxWDZGNjBsWTFTRmYzRWk3V3JQRFlPbVp3N0V2Yy1nM19DRH…
GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiggJBVV95cUxNTTR1Ujc2eTd6ZEx4Z2RYdmx3S21JeGx4NmZtREsyaWxKNnJPNFl5R1pSZVdYdjNxMlo3V3gtLW5lVHJVTk4xeHlxZk05LWVrUDN6VGZOUHlJdUF1LWpkMUxqVDJRRkEzZlBxdW5aMEVpb0F5dGt2eC1HNHpRSEk2cmlPVnV6WWFiSEk1aU…
Galectin Therapeutics (NASDAQ:GALT) Share Price Passes Above Two Hundred Day Moving Average - Here's Why - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxNTlJVS004R2VXLURHTW1Jak1jYVRDZWxsbng5b3lycE9OYWpIX09veV9oUEpFZDBSY3Z1c2FwUUl6VmpnU01KS2RlaDA0TXZIVldYbWgxNWhTRk5ieFZvMXY5UTFjOUpHeFFPbTIzdko4VWF0Wno4WjI4UGRaMWlVU2h5a01yLV9xcG5ZNj…
Richard Uihlein converts GALT debt into 34,376,167 new shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPZjFYblJtUE1NRnNWR3R2TmFwU1FHejlKeGdEV0l1UC1seDUxU1FuVUhUTDBhYTBJWmtsWXdBbThONVVRODllSzdUTmZscGpUa012Q2hkdDlfTHZxRHJiZnN5VWZTZE04TTQ5MHdjVVhENHZrQkVXeXZ4N0hSc1NtdXo3OHRSVDZrVzEtRE…
GALT — Frequently Asked Questions
What is the current share price of GALT?
As of 2026-08-05 17:25 PDT, GALT trades at $3.09 on NASDAQ/NYSE. Its 52-week range is $2.08 to $6.51.
What is the P/E ratio of GALT?
GALT trades at a trailing price-to-earnings (P/E) ratio of -6.44.
What is the return on equity (ROE) of GALT?
GALT has a return on equity (ROE) of 24.11%.
Is GALT a good stock to buy?
This page provides a data-driven analysis of GALT, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.